<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00137007</url>
  </required_header>
  <id_info>
    <org_study_id>A0661082</org_study_id>
    <nct_id>NCT00137007</nct_id>
  </id_info>
  <brief_title>Zithromax EV in Community-Acquired Pneumonia (CAP)</brief_title>
  <official_title>A Multicenter, Open Label Trial Evaluating Intravenous Azithromycin Plus Intravenous Ampicillin/Sulbactam Followed by Oral Azithromycin Plus Intravenous Ampicillin/Sulbactam for the Treatment of Hospitalized Subjects With Community-Acquired Pneumonia (CAP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <brief_summary>
    <textblock>
      The intravenous (IV) regimen containing azithromycin (Zithromax) plus ampicillin-sulbactam is&#xD;
      consistent with current guidelines for the treatment of CAP. In fact the International&#xD;
      guidelines for the treatment of CAP in hospitalised patients suggests the use of a&#xD;
      combination between a b-lactam and a macrolide.&#xD;
&#xD;
      This trial will allow investigators to evaluate the efficacy of azithromycin plus&#xD;
      ampicillin-sulbactam in the treatment of hospitalized subjects with community acquired&#xD;
      pneumonia. In addition, this trial will allow investigators to evaluate the safety and&#xD;
      toleration of combination therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">September 2005</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the clinical efficacy of intravenous (IV) azithromycin 500 mg once daily plus IV ampicillin/sulbactam 3 grams twice a day (BID) for 2 to 5 days</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>followed by oral azithromycin 500 mg once daily plus IV ampicillin/sulbactam 3 grams.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the eradication of baseline pathogens of IV azithromycin plus IV ampicillin/sulbactam followed by oral azithromycin plus IV ampicillin/sulbactam at Visit 3 and Visit 4</measure>
  </secondary_outcome>
  <enrollment type="Actual">151</enrollment>
  <condition>Pneumonia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ampicillin/sulbactam</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must require hospitalization and intravenous therapy.&#xD;
&#xD;
          -  Subjects must have a Fine pneumonia score &gt; 70 (Fine Class &gt; II).&#xD;
&#xD;
          -  Subjects must have a medical history and clinical and radiological findings consistent&#xD;
             with a community-acquired bronchopneumonia or lobar pneumonia. The following criteria&#xD;
             must be met:&#xD;
&#xD;
               -  new infiltrate(s) on chest X-ray; AND&#xD;
&#xD;
               -  at least two of the CAP signs or symptoms.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with any systemic antibiotic for 24 hours or longer within 72 hours of the&#xD;
             baseline visit, or treatment for more than 7 days within 15 days.&#xD;
&#xD;
          -  Specific systemic diseases or other medical conditions that would interfere with the&#xD;
             evaluation of the therapeutic response or safety of the study drug, including:&#xD;
&#xD;
               -  Known acquired immunodeficiency syndrome (AIDS) or suspected Pneumocystis carinii&#xD;
                  pneumonia;&#xD;
&#xD;
               -  Neutropenia;&#xD;
&#xD;
               -  Cavitary lung disease by chest X-ray;&#xD;
&#xD;
               -  Primary lung cancer or other malignancy metastatic to the lung;&#xD;
&#xD;
               -  Aspiration pneumonia;&#xD;
&#xD;
               -  Empyema;&#xD;
&#xD;
               -  Known or suspected tuberculosis;&#xD;
&#xD;
               -  Neoplastic disease;&#xD;
&#xD;
               -  Cystic fibrosis;&#xD;
&#xD;
               -  A history of any form of epilepsy or seizure;&#xD;
&#xD;
               -  DDM;&#xD;
&#xD;
               -  Bronchiectasis, bronchial obstruction or history of post-obstructive pneumonia&#xD;
                  (this does not exclude patients with chronic obstructive pulmonary disease);&#xD;
&#xD;
               -  Significant gastrointestinal or other conditions which may affect study drug&#xD;
                  absorption; and&#xD;
&#xD;
               -  Significant cardiovascular disorders.&#xD;
&#xD;
          -  Immunosuppressive therapy, defined as chronic treatment with known immunosuppressant&#xD;
             medications&#xD;
&#xD;
          -  Impaired hepatic function, as shown by, but not limited to, AST, (SGOT), or ALT (SGPT)&#xD;
             greater than three times the laboratory upper limit of normal, or total bilirubin&#xD;
             greater than two times the upper limit of normal.&#xD;
&#xD;
          -  Subjects already hospitalized or who resided in a long-term-care facility for greater&#xD;
             than 14 days before the onset of symptoms.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <removed_countries>
    <country>Italy</country>
  </removed_countries>
  <verification_date>April 2011</verification_date>
  <study_first_submitted>August 25, 2005</study_first_submitted>
  <study_first_submitted_qc>August 25, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2005</study_first_posted>
  <last_update_submitted>April 20, 2011</last_update_submitted>
  <last_update_submitted_qc>April 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2011</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Ampicillin</mesh_term>
    <mesh_term>Sulbactam</mesh_term>
    <mesh_term>Sultamicillin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

